{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:33:17Z","timestamp":1793370797839,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clinme.2026.100634","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T06:15:21Z","timestamp":1786342521000},"page":"100634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["What is new in tuberculosis?"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5211-2282","authenticated-orcid":false,"given":"Ye","family":"Myat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Cerrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onn Min","family":"Kon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clinme.2026.100634_bib1","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.3390\/ijms24065202","article-title":"Tuberculosis: pathogenesis, current treatment regimens and new drug targets","volume":"24","author":"Alsayed","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinme.2026.100634_bib2","series-title":"Global Tuberculosis Report 2025","author":"World Health Organization","year":"2025"},{"issue":"8","key":"10.1016\/j.clinme.2026.100634_bib3","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/thoraxjnl-2018-211537","article-title":"Trends in tuberculosis in the UK","volume":"73","author":"Glaziou","year":"2018","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.clinme.2026.100634_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0041-3879(73)80029-7","article-title":"A tuberculosis survey in England and Wales 1971; the influence of immigration and country of birth upon notifications: a report from the Research Committee of the British Thoracic and Tuberculosis Association","volume":"54","author":"Research Committee of the British Thoracic and Tuberculosis Association","year":"1973","journal-title":"Tubercle"},{"key":"10.1016\/j.clinme.2026.100634_bib5","series-title":"Reports of Cases of TB to UK Enhanced Tuberculosis Surveillance Systems, England: 2000\u20132024 Report","author":"UK Health Security Agency","year":"2025"},{"key":"10.1016\/j.clinme.2026.100634_bib6","series-title":"Tuberculosis in England, 2025 Report (Data up to End of 2024","author":"Cox","year":"2025"},{"key":"10.1016\/j.clinme.2026.100634_bib7","doi-asserted-by":"crossref","first-page":"q2758","DOI":"10.1136\/bmj.q2758","article-title":"Tuberculosis: health chiefs issue warning over rise in cases","volume":"387","author":"Wise","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.clinme.2026.100634_bib8","series-title":"Tuberculosis (TB): Action Plan for England, 2021\u20132026","author":"UK Health Security Agency, NHS England","year":"2023"},{"issue":"7","key":"10.1016\/j.clinme.2026.100634_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/tropicalmed10070190","article-title":"Risk of latent tuberculosis infection reactivation in patients treated with tumor necrosis factor antagonists: a five-year retrospective study","volume":"10","author":"Aliravci","year":"2025","journal-title":"Trop Med Infect Dis"},{"issue":"6","key":"10.1016\/j.clinme.2026.100634_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TNMI7-0026-2016","article-title":"Biologic agents and tuberculosis","volume":"4","author":"Dobler","year":"2016","journal-title":"Microbiol Spectr"},{"issue":"3","key":"10.1016\/j.clinme.2026.100634_bib11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/hdi.13010","article-title":"Diagnosis of tuberculosis in dialysis and kidney transplant patients","volume":"26","author":"Ali","year":"2022","journal-title":"Hemodial Int"},{"issue":"1","key":"10.1016\/j.clinme.2026.100634_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2025.106668","article-title":"Tuberculosis incidence in solid organ transplant recipients in Europe: a multicenter TBnet cohort study","volume":"92","author":"Lange","year":"2026","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.clinme.2026.100634_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/jgid.jgid_112_24","article-title":"Tuberculosis diagnosis and management: recent advances","volume":"17","author":"Shrivas","year":"2025","journal-title":"J Glob Infect Dis"},{"key":"10.1016\/j.clinme.2026.100634_bib14","series-title":"WHO Consolidated Guidelines on Tuberculosis. Module 3: Diagnosis \u2013 Rapid Diagnostics for Tuberculosis Detection","author":"World Health Organization","year":"2024"},{"key":"10.1016\/j.clinme.2026.100634_bib15","series-title":"Tuberculosis. NICE Guideline [NG33]","author":"National Institute for Health and Care Excellence","year":"2016"},{"key":"10.1016\/j.clinme.2026.100634_bib16","series-title":"Prioritisation Board Decisions 2025 [Internet]","author":"National Institute for Health and Care Excellence","year":"2025"},{"issue":"7","key":"10.1016\/j.clinme.2026.100634_bib17","article-title":"Xpert MTB\/RIF Ultra assay for pulmonary tuberculosis and rifampicin resistance in adults and adolescents","volume":"7","author":"Horne","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.clinme.2026.100634_bib18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/14787210.2020.1810565","article-title":"Use of Xpert MTB\/RIF and Xpert Ultra in extrapulmonary tuberculosis","volume":"19","author":"Park","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"9","key":"10.1016\/j.clinme.2026.100634_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0331264","article-title":"Evaluation of the Xpert MTB\/XDR test for detection of isoniazid, fluoroquinolones, and second-line injectable drugs resistance to Mycobacterium tuberculosis-Anhui Province, China","volume":"20","author":"Zhang","year":"2025","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.clinme.2026.100634_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae437","article-title":"Reflex Xpert MTB\/XDR testing of residual rifampicin-resistant specimens: a clinical laboratory-based diagnostic accuracy and feasibility study in South Africa","volume":"11","author":"Centner","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.clinme.2026.100634_bib21","article-title":"Xpert MTB\/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin","volume":"5","author":"Pillay","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.clinme.2026.100634_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.01054-23","article-title":"Evaluation of the fluorotype Mycobacteria assay for identification of mycobacteria","volume":"62","author":"Luukinen","year":"2024","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.clinme.2026.100634_bib23","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41597-025-04966-1","article-title":"Comprehensive whole genome sequencing dataset of Mycobacterium tuberculosis strains collected across Italy","volume":"12","author":"Ghodousi","year":"2025","journal-title":"Sci Data"},{"issue":"8","key":"10.1016\/j.clinme.2026.100634_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00666-18","article-title":"Direct whole-genome sequencing of sputum accurately identifies drug-resistant Mycobacterium tuberculosis faster than MGIT culture sequencing","volume":"56","author":"Doyle","year":"2018","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.clinme.2026.100634_bib25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12864-019-5782-2","article-title":"Whole genome sequencing Mycobacterium tuberculosis directly from sputum identifies more genetic diversity than sequencing from culture","volume":"20","author":"Nimmo","year":"2019","journal-title":"BMC Genom"},{"key":"10.1016\/j.clinme.2026.100634_bib26","series-title":"Mycobacterium tuberculosis Whole-genome Sequencing and Cluster Investigation Handbook","author":"UK Health Security Agency","year":"2022"},{"key":"10.1016\/j.clinme.2026.100634_bib27","series-title":"Catalogue of Mutations in Mycobacterium tuberculosis Complex and their Association With Drug Resistance","author":"World Health Organization","year":"2023"},{"issue":"10","key":"10.1016\/j.clinme.2026.100634_bib28","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1473-3099(24)00263-9","article-title":"Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"24","author":"Schwab","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.clinme.2026.100634_bib29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12890-024-02893-2","article-title":"Improving the diagnosis of active tuberculosis: a novel approach using magnetic particle-based chemiluminescence LAM assay","volume":"24","author":"Li","year":"2024","journal-title":"BMC Pulm Med"},{"issue":"3","key":"10.1016\/j.clinme.2026.100634_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00227-21","article-title":"Tuberculosis treatment monitoring and outcome measures: new interest and new strategies","volume":"35","author":"Heyckendorf","year":"2022","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"10.1016\/j.clinme.2026.100634_bib31","article-title":"Study on artificial intelligence to judge the activity of tuberculomas","volume":"17","author":"Wei","year":"2024","journal-title":"J\u00a0Radiat\u00a0Res\u00a0Appl Sci"},{"issue":"6","key":"10.1016\/j.clinme.2026.100634_bib32","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1586\/17476348.2016.1166960","article-title":"Assessment of treatment response in tuberculosis","volume":"10","author":"Rockwood","year":"2016","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.clinme.2026.100634_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.76","article-title":"Tuberculosis","volume":"2","author":"Pai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clinme.2026.100634_bib34","doi-asserted-by":"crossref","DOI":"10.1590\/s1678-9946202365013","article-title":"QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-tube assays for detecting latent tuberculosis infection in Thai healthcare workers","volume":"65","author":"Rudeeaneksin","year":"2023","journal-title":"Rev Inst Med Trop Sao Paulo"},{"issue":"1","key":"10.1016\/j.clinme.2026.100634_bib35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1128\/CMR.00034-13","article-title":"Gamma interferon release assays for detection of Mycobacterium tuberculosis infection","volume":"27","author":"Pai","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.clinme.2026.100634_bib36","article-title":"Indeterminate results of interferon gamma release assays in the screening of latent tuberculosis infection: a systematic review and meta-analysis","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.clinme.2026.100634_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad228","article-title":"A systematic review on the safety of Mycobacterium tuberculosis-specific antigen-based skin tests for tuberculosis infection compared with tuberculin skin tests","volume":"10","author":"Hamada","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.clinme.2026.100634_bib38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1128\/CDLI.7.2.155-160.2000","article-title":"Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10","volume":"7","author":"van Pinxteren","year":"2000","journal-title":"Clin Diagn Lab Immunol"},{"issue":"2","key":"10.1016\/j.clinme.2026.100634_bib39","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1473-3099(21)00261-9","article-title":"The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-gamma release assays: a systematic review and meta-analysis","volume":"22","author":"Krutikov","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clinme.2026.100634_bib40","series-title":"WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment and Care","author":"World Health Organization","year":"2025"},{"issue":"18","key":"10.1016\/j.clinme.2026.100634_bib41","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clinme.2026.100634_bib42","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00388-2022","article-title":"Rifapentine access in Europe: growing concerns over key tuberculosis treatment component","volume":"59","author":"Guglielmetti","year":"2022","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.clinme.2026.100634_bib43","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2104535","article-title":"Shorter treatment for nonsevere tuberculosis in African and Indian children","volume":"386","author":"Turkova","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clinme.2026.100634_bib44","doi-asserted-by":"crossref","first-page":"277","DOI":"10.12701\/yujm.2020.00626","article-title":"Diagnosis and treatment of multidrug-resistant tuberculosis","volume":"37","author":"Jang","year":"2020","journal-title":"Yeungnam Univ J Med"},{"issue":"10366","key":"10.1016\/j.clinme.2026.100634_bib45","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(22)02078-5","article-title":"Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial","volume":"400","author":"Goodall","year":"2022","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.clinme.2026.100634_bib46","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang'wa","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clinme.2026.100634_bib47","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clinme.2026.100634_bib48","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clinme.2026.100634_bib49","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1164\/rccm.202107-1779OC","article-title":"An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT study)","volume":"205","author":"Esmail","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinme.2026.100634_bib50","article-title":"BEAT tuberculosis: a randomized controlled trial of a 6-month strategy for rifampicin-resistant tuberculosis","author":"Conradie","year":"2025","journal-title":"medRxiv"},{"issue":"5","key":"10.1016\/j.clinme.2026.100634_bib51","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa2400327","article-title":"Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis","volume":"392","author":"Guglielmetti","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clinme.2026.100634_bib52","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41579-022-00731-y","article-title":"Anti-tuberculosis treatment strategies and drug development: challenges and priorities","volume":"20","author":"Dartois","year":"2022","journal-title":"Nat Rev Microbiol"},{"issue":"8","key":"10.1016\/j.clinme.2026.100634_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11081304","article-title":"Next-generation TB vaccines: progress, challenges, and prospects","volume":"11","author":"Zhuang","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.clinme.2026.100634_bib54","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.molimm.2025.04.016","article-title":"Goals and strategies in vaccine development against tuberculosis","volume":"183","author":"Konjengbam","year":"2025","journal-title":"Mol Immunol"},{"issue":"25","key":"10.1016\/j.clinme.2026.100634_bib55","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final analysis of a trial of M72\/AS01(E) vaccine to prevent tuberculosis","volume":"381","author":"Tait","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211826000837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211826000837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:55:38Z","timestamp":1793368538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211826000837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1470211826000837"],"URL":"https:\/\/doi.org\/10.1016\/j.clinme.2026.100634","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What is new in tuberculosis?","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinme.2026.100634","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of Royal College of Physicians.","name":"copyright","label":"Copyright"}],"article-number":"100634"}}